Abstract: Embodiments of the present invention provide methods and devices for performing wireless sensing operations that can accommodate different Rx frequency responses with minimum PHY changes to increase the performance and reliability of wireless sensing in wireless local area network (WLAN) networks. Rx frequency response information can be obtained as channel state information (CSI) in a loopback test and can further be normalized with the total gain in the receiver chain leading to CSI estimation. Moreover, different Rx frequency responses can be categorized into limited groups with underlying circuit conditions based on their frequency response variations. The different Rx frequency responses can be indicated in subfields of a CSI report transmitted to the sensing initiator for performing sensing operations with the sensing responder.

Abstract: Disclosed herein are novel pharmaceutical formulations of a neurokinin-1 (NK-1) receptor antagonist suitable for parenteral administration including intravenous administration. Also included are formulations including both the NK-1 receptor antagonist and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.

Abstract: A medical product includes a bladder, a filtration device, and a sterile product concentrate. The bladder has a perimeter seal and defining a sterile chamber. The filtration device includes a stem and a filter membrane disposed in line with the stem. The stem extends through the perimeter seal and has an inlet end accessible from outside of the perimeter seal and an outlet end in fluid communication with the sterile chamber. The filter membrane can have a nominal pore size in a range of approximately 0.1 ?m to approximately 0.5 ?m, wherein the filter membrane is shaped as a hollow fiber with a wall and pores residing in the wall of the fiber. The sterile product concentrate is disposed in the sterile chamber and adapted to be reconstituted by the introduction of a pharmaceutical fluid into the chamber through the filtration device.

Abstract: A method for displaying lane information on an augmented reality display includes receiving roadway data. The roadway data includes information about a roadway along a route of a vehicle. The roadway includes a plurality of lanes. The roadway data includes lane information about at least one of the plurality of lanes along the route of the vehicle. The method further includes receiving vehicle-location data. The vehicle-location data indicates a location of the vehicle. The method further includes determining that that the vehicle is approaching a road junction using the vehicle-location data and the roadway data. The method further includes, in response to determining that the vehicle is approaching the road junction, transmitting a command signal to a dual-focal plane augmented reality display to display at least one virtual image that is indicative of the lane information.

Abstract: A pupil replicator for a head up display system includes a waveguide adapted to receive an incoming image beam, and including a transparent body having a partially transmissive top surface and a reflective bottom surface, a Dammann grating adapted to create a plurality of duplicate image beams having equal intensity, and reflect each of the plurality of duplicate image beams within the waveguide, and a beam aligning device adapted to receive each of the plurality of duplicate image beams and to reflect each of the plurality of duplicate image beams at a common angle relative to the waveguide, wherein, after being reflected by the beam aligning device, each of the plurality of duplicate image beams are parallel to one another.

Abstract: Disclosed herein are novel pharmaceutical formulations of aprepitant suitable for parenteral administration including intravenous administration. Also included are formulations including both aprepitant and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.

Abstract: Disclosed herein are novel pharmaceutical formulations of a neurokinin-1 (NK-1) receptor antagonist suitable for parenteral administration including intravenous administration. Also included are formulations including both the NK-1 receptor antagonist and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.

Abstract: A hybrid augmented reality head-up display system for displaying graphics upon a windscreen of a vehicle includes a windscreen having a transparent substrate including light emitting particles dispersed within, a primary graphic projection device for generating a first set of images upon the windscreen of the vehicle based on visible light, and a secondary graphic projection device for generating a second set of images upon a secondary area the windscreen of the vehicle based on an excitation light. The first set of images are displayed upon a primary area of the windscreen. The light emitting particles in the windscreen emit visible light in response to absorbing the excitation light. The first set of images displayed upon the primary area of the windscreen cooperate with the second set of images displayed upon the secondary area of the windscreen to create an edge-to-edge augmented reality view.

Abstract: A compound represented by one of the formulae: BaaMobOc??(1), MOdPeOf??(2) or BagMohPiOj??(3) wherein for formula (1) the ratio of a:b is greater than 1:1, wherein for formula (2) the ratio of d:e is from 1:100 to 0.45:1 or from 0.55:1 to 100:1, wherein for formula (3) the ratio of g:h is from 1:7 to 1:2 and the ratio of g:i is from 1:3 to 1:1, or the ratio of g:h is from 0.6:1 to 100:1 and the ratio of g:i is from 2.2:1 to 100:1, and wherein the molybdenum present within the compound is in the 4+ oxidation state.

Abstract: An apparatus and system are provided to enable the co-existence of small data transmission (SDT) and core network (CN) buffering when a user equipment (UE) is in an inactive state. A message transmitted from a user plane function (UPF) includes a Quality of Service (QoS) Flow Indicator (QFI) and data volume information (DVI) of buffered data in the UPF while the UE is in the inactive state. The QFI and DVI is provided to a next generation radio access network (NG-RAN). Based on the QFI and DVI, the RAN determines whether to page the UE for a mobile terminated SDT (MT-SDT) and whether to trigger connection resumption due to SDT. If connection resumption is triggered, the NG-RAN keeps the UE in the inactive state while an SDT session is initiated. At the end of the SDT session, the NG-RAN re-activates CN buffering.

Abstract: A compound represented by one of the formulae: BaaMobOc??(1), MOdPeOf??(2) or BagMohPiOj??(3) wherein for formula (1) the ratio of a:b is from 1:100 to 100:1, wherein for formula (2) the ratio of d:e is from 1:100 to less than 1:1 or from greater than 1:1 to 100:1, wherein for formula (3) the ratio of g:h is from 1:100 to less than 1.5:1, wherein for formula (3) the ratio of g:i is from 1:100 to 100:1, wherein for formula (3) the ratio of h:i is from 1:100 to less than 1:2, or from greater than 1:2 to less than 2:1, or from greater than 2:1 to 100:1, and wherein the molybdenum present within the compound is in the 5+ oxidation state.

Abstract: Provided herein are bispecific antigen-binding molecules that bind HER2 and methods of use thereof. The bispecific antigen-binding molecules comprise a first and a second antigen-binding domain, wherein the first and second antigen-binding domains bind to two different (preferably non-overlapping) epitopes of the extracellular domain of human HER2. The bispecific antigen-binding molecules cluster on the surface of HER2 IHC2+ and IHC3+ cells, and are internalized into the cellular lysosomes. Also included are antibody-drug conjugates (ADCs) comprising the antibodies or bispecific antigen-binding molecules provided herein linked to a cytotoxic agent, radionuclide, or other moiety, as well as methods of treating cancer in a subject by administering to the subject a bispecific antigen-binding molecule or an ADC thereof.

Abstract: A copper electroplating solution comprising a copper salt, a source of halide ions, and a linear or branched polyhydroxyl. The copper electroplating solution is used to deposit copper having a high density of nanotwinned columnar copper grains on a substrate. The linear or branched polyhydroxyl may comprise a reaction product between 2,3-epoxy-1-propanol and aminic alcohol or ammonium alcohol.

Abstract: A holographic projection system includes a SLM that receives a light beam and generates a modulated beam projected at an eyebox, where: the modulated beam includes multiple versions of a test image; and the test image includes bright objects and transparent regions, which are selected dark areas of interest for measuring luminance. A control module runs a test to characterize contrast in each of multiple virtual image planes including: controlling the SLM to generate the modulated beam; measuring luminance levels of each of the versions of the test image displayed in the virtual image planes; calculating contrast ratios based on the luminance levels of each of the versions of the test image; determining whether the contrast ratios are within predetermined ranges of predetermined contrast ratios; and adjusting operation of the SLM in response to one of the contrast ratios not being within a corresponding one of the predetermined ranges.

Abstract: A method and a system for user interaction with a hologram includes displaying the hologram inside a passenger compartment of the vehicle, after displaying the hologram inside the passenger compartment of the vehicle, monitoring a vehicle user inside the passenger compartment of the vehicle to determine whether the vehicle user provided a user command, determining that the vehicle user provided the user command, and in response to determining that the vehicle user provided the user command, manipulating the hologram in accordance with the user command.

Abstract: In accordance with one aspect of the presently disclosed inventive concepts, a metal aerogel includes a plurality of metal nanowires formed into a porous three-dimensional structure, where pores in the structure are anisotropic.

Abstract: The present disclosure relates to a bridging asymmetric haloalkynyl dicobalt hexacarbonyl precursors, and ultra high purity versions thereof, methods of making, and methods of using these bridging asymmetric haloalkynyl dicobalt hexacarbonyl precursors in a vapor deposition process. One aspect of the disclosure relates to an ultrahigh purity bridging asymmetric haloalkynyl dicobalt hexacarbonyl precursor of the formula Co2(CO)6(R3C?CR4), where R3 and R4 are different organic moieties and R4 is more electronegative or more electron withdrawing compared to R3.

Abstract: A method for displaying infrastructure information on a multi-focal plane augmented reality display of a vehicle includes receiving infrastructure data. The infrastructure data includes information about a location of at least one infrastructure along a route of the vehicle. The method further includes receiving vehicle-location data. The vehicle-location data includes information about a location of the vehicle. The method further includes determining a position of the vehicle relative to the location of the least one infrastructure using the infrastructure data and the vehicle-location data. The method further includes transmitting a command signal to the multi-focal plane augmented reality display to display a virtual image showing the infrastructure information of the infrastructure on the multi-focal plane augmented reality display.

Abstract: The disclosure provides compounds of Formula (I) or a pharmaceutically acceptable salt thereof, wherein W1, W2, Y, Z, M, L, CY, Cz, R1, R2, R3, R4, R2a, Ry, Rz, and the subscripts m, n, q, and r are as described herein. The compounds or their pharmaceutically acceptable salts can inhibit the G12C mutant of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.

Abstract: A method for operating a fuel injection system is provided. The method includes injecting fuel from a first direct fuel injection device arranged in a cylinder liner in a cylinder block into a combustion chamber and injecting fuel from a second direct fuel injection device arranged in a cylinder head into the combustion chamber, the first and second direct fuel injection devices arranged at an obtuse angle with regard to an intersection of central axes of the first and second direct fuel injection devices.